05 December 2008
No evidence for PERV release by islet cells from German landrace pigs
Markus Irgang, Christine Laue, Florian Velten, Reinhard Kurth, Jürgen Schrezenmeier, Joachim DennerAnn Transplant 2008; 13(4): 59-66 :: ID: 880220
Abstract
Background: Islet cells from pig could be used as an alternative to the current treatment of diabetic patients. However, xenotransplantation from pig to humans may be associated with the risk of transmission of porcine endogenous retroviruses (PERVs) that are present in the genome of all pigs and infect human cells in vitro. Although transplantation of pig islet cells for treatment of diabetes may be not accompanied by immunosuppression that may facilitate virus survival, since islets will be used encapsulated, it is nevertheless of importance to study whether islet cells release PERVs able to infect human cells during co-incubation.
Material/Methods: Isolated islets from German landrace pigs were incubated with highly susceptible human 293 cells for one week. In order to prevent microchimerism 293 cells were made neomycin-resistant (293[sup]neo+[/sup]), that allows the elimination of pig cells by a selection medium. The infection of 293[sup]neo+ [/sup]target cells was analysed by PCR using PERV-specific primers up to five weeks after co-cultivation. In addition, expression of viral mRNA in pig islet cells was studied by RT-PCR analysis, the expression of viral protein by FACS analysis.
Results: Despite the presence of numerous PERV proviruses in the genome of all pigs, no expression of PERV was observed in German landrace pig islet cells, neither as mRNA, nor as protein, nor as viral particles.
Conclusions: Islet cells from German landrace pigs do not express PERVs and may therefore be used for breeding genetically modified pigs suitable for xenotransplantation and treatment of diabetes.
Keywords: Xenotransplantation, Diabetes, Porcine Endogenous Retroviruses (PERV), islet cells
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






